Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Seres Therapeutics Inc shares valued at $459 were sold by Young Teresa L. on May 16 ’25. At $7.28 per share, Young Teresa L. sold 63 shares. The insider’s holdings dropped to 5,044 shares worth approximately $38990.12 following the completion of this transaction.
Also, Shaff Eric D. sold 220 shares, netting a total of over 1,602 in proceeds. Following the sale of shares at $7.28 each, the insider now holds 10,102 shares.
Before that, DesRosier Thomas had sold 79 shares from its account. In a trade valued at $575, the Chief Legal Officer and EVP traded Seres Therapeutics Inc shares for $7.28 each. Upon closing the transaction, the insider’s holdings decreased to 79 shares, worth approximately $56328.51.
As published in a research note from Chardan Capital Markets on May 08, 2025, Seres Therapeutics Inc [MCRB] has been rated down from a Buy to a Neutral and the price target has been revised to $6. Analysts at JP Morgan downgraded the stock from ‘”a Neutral”‘ to ‘”an Underweight”‘ outlook in a report released in late October. Earlier on April 21, 2023, JP Morgan initiated its rating. Their recommendation was “a Neutral” for MCRB stock.
Analyzing MCRB Stock Performance
On last trading session,, Seres Therapeutics Inc [NASDAQ: MCRB] rose 5.60% to $7.73. During the last five days, there has been a drop of approximately -3.74%. Over the course of the year, Seres Therapeutics Inc shares have dropped approximately -53.49%. Shares of the company reached a 52-week high of $19.05 on 01/23/25 and a 52-week low of $6.53 on 05/15/25.
Support And Resistance Levels for Seres Therapeutics Inc (MCRB)
According to the 24-hour chart, there is a support level at 7.36, which, if violated, would cause prices to drop to 6.99. In the upper region, resistance lies at 7.99. The next price resistance is at 8.26. RSI (Relative Strength Index) is 47.89 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of Seres Therapeutics Inc (MCRB)?
In terms of Seres Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 1.25 in the next 12 months, down nearly -82.92% from the previous closing price of $7.32. Analysts anticipate Seres Therapeutics Inc stock to reach 1.25 by 2025, with the lowest price target being 1.25. In spite of this, 3 analysts ranked Seres Therapeutics Inc stock as Buy at the end of 2025. On July 23, 2021, Goldman assigned a price target of “a Sell” to the stock and downgraded coverage with a $7.
